BioCentury
ARTICLE | Deals

Novo, Prothena strike deal for ATTR therapy with depleter mechanism

The program targets patients not well served by other approaches

July 12, 2021 8:39 PM UTC

Novo is further expanding its CV footprint by acquiring a clinical program from Prothena that may be able to reach a population of high-risk amyloidosis patients not well served by Pfizer’s Vyndaqel/Vyndamax or TTR-silencing therapies.

Novo Nordisk A/S (CSE:NOVO B; NYSE:NVO) is paying Prothena Corp. plc (NASDAQ:PRTA) $60 million up front to acquire the biotech’s entire transthyretin amyloidosis (ATTR) program including PRX004, a mAb that targets misfolded TTR. Prothena is eligible for more than $1.1 billion in additional development and commercial milestones, including a $40 million near-term milestone...

BCIQ Target Profiles

Transthyretin (TTR)